<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663829</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-728</org_study_id>
    <nct_id>NCT03663829</nct_id>
  </id_info>
  <brief_title>Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia</brief_title>
  <official_title>Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Patients With Rheumatoid Arthritis Who Are Treated With Abatacept or Tumour Necrosis Factor Inhibitors. An Analysis From the Optimising Patient Outcome in Australian Rheumatology (OPAL) Registry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational study assessing the impact of anti-citrullinated antibody (ACPA) in
      rheumatoid arthritis (RA) participants who have received abatacept or tumour necrosis factor
      inhibitors (TNFi) from the Optimising Patient outcome in Australian rheumatoLogy (OPAL)
      registry
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">March 29, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ACPA (Anti-cyclic citrullinated peptide) status</measure>
    <time_frame>Pre-Index</time_frame>
    <description>ACPA-positive greater than or equal to 5 Ru/mL in Australia, greater than or equal to 20 Ru/mL in US</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive ACPA</measure>
    <time_frame>Index</time_frame>
    <description>ACPA-positive greater than or equal to 5 Ru/mL in Australia, greater than or equal to 20 Ru/mL in US</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with negative ACPA</measure>
    <time_frame>Index</time_frame>
    <description>ACPA-negative less than or equal to 5 Ru/mL in Australia, less than or equal to 20 Ru/mL in US</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI (clinical disease activity index) score</measure>
    <time_frame>Index plus or minus 1 month</time_frame>
    <description>Remission CDAI &lt;2.9 Low disease activity CDAI ≥ 2.9 but &lt;10.0 Moderate disease activity CDAI ≥ 10.1 but &lt;22.0 High disease activity CDAI ≥ 22.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI (clinical disease activity index) score</measure>
    <time_frame>12 months plus or minus 3 months</time_frame>
    <description>Remission CDAI &lt;2.9 Low disease activity CDAI ≥ 2.9 but &lt;10.0 Moderate disease activity CDAI ≥ 10.1 but &lt;22.0 High disease activity CDAI ≥ 22.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 (disease activity score 28)-CRP-3 (C reactive protein) score</measure>
    <time_frame>Index plus or minus 1 month</time_frame>
    <description>The DAS-28 CRP-3 is a measure of disease activity in rheumatoid arthritis (RA) that assesses 28 joints in RA commonly affected. The DAS-28 CRP 3 takes into account tender and swollen joint counts and CRP level (measure of inflammation in the blood). The DAS-28 CRP 3 measure does not include patient global assessment of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 (disease activity score 28)-CRP-3 (C reactive protein) score</measure>
    <time_frame>12 months plus or minus 3 months</time_frame>
    <description>The DAS-28 CRP-3 is a measure of disease activity in rheumatoid arthritis (RA) that assesses 28 joints in RA commonly affected. The DAS-28 CRP 3 takes into account tender and swollen joint counts and CRP level (measure of inflammation in the blood). The DAS-28 CRP 3 measure does not include patient global assessment of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment persistence</measure>
    <time_frame>Approximately 11 years and 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment discontinuation</measure>
    <time_frame>Approximately 11 years and 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants identified as taking abatacept</measure>
    <time_frame>Index</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants identified as taking TNFi (tumor necrosis factor inhibitor)</measure>
    <time_frame>Index</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that achieved remission</measure>
    <time_frame>12 months plus or minus 3 months</time_frame>
    <description>Remission CDAI &lt;2.9 Low disease activity CDAI ≥ 2.9 but &lt;10.0 Moderate disease activity CDAI ≥ 10.1 but &lt;22.0 High disease activity CDAI ≥ 22.0</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Participants RA who have received a TNFi</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with RA who have received abatacept</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Participants RA who have received a TNFi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Participants with RA who have received abatacept</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of rheumatoid arthritis (RA) who have received a TNFi or
        abatacept and registered in the OPAL registry
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with rheumatoid arthritis

          -  Have a baseline ACPA recorded

          -  Received either abatacept or a TNFi (adalimumab, certolizumab, etanercept or
             golimumab) during the sample selection window 1 August 2006 to 30 June 2017

        Exclusion Criteria:

          -  Patients who have died

          -  Patients with concomitant inflammatory diseases (e.g. ankylosing spondylitis,
             psoriatic arthritis, Crohn's disease, ulcerative colitis)

          -  Patients who have no visit data recorded (even if medication data is available)

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Canberra City</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS (Bristol-Myers Squibb) Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

